ERBB2 and cancer: T-DXd is an antibody-drug conjugate that combines trastuzumab, a monoclonal antibody targeting HER2, with a topoisomerase I inhibitor via a cleavable linker for precise delivery of cytotoxic agents to HER2-expressing cancer cells (Nakada et al., 2019).